The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents

Drugs
F GayAntonio Palumbo

Abstract

Outcome of patients with multiple myeloma (MM) has greatly improved with the use of autologous stem cell transplantation (ASCT) and new agents, such as immunomodulatory drugs (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib). When compared to conventional chemotherapy, high-dose melphalan with ASCT significantly improved response rates and progression-free survival, while overall survival benefit was not consistent across all trials. ASCT is considered the standard treatment for patients who are younger than 65 years and who do not have limiting comorbidities. New, effective agents have been introduced as part of induction, consolidation and maintenance treatments within ASCT and in combinations with chemotherapy for patients not eligible for ASCT. The remarkable results obtained with these regimens are questioning the role of ASCT for newly diagnosed MM patients. This article aims to delineate the role of ASCT in the era of novel agents based on the results of recent clinical trials.

References

Jan 6, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Fritz, H Ludwig
Jul 10, 2001·British Journal of Haematology·UNKNOWN Myeloma Trialists' Collaborative Group
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome
Jan 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart BarlogieJohn C Crowley
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
May 9, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele CavoMichele Baccarani
Jun 27, 2007·British Journal of Haematology·Bart BarlogieJohn D Shaughnessy
Jul 4, 2007·Haematologica·Pieter SonneveldUNKNOWN Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SpencerNola Kennedy
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele CavoMichele Baccarani
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco LadettoAntonio Palumbo
Mar 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno PaivaJesus F San Miguel
Jan 25, 2012·Blood·Heinz LudwigUNKNOWN International Myeloma Working Group
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Jun 26, 2012·American Journal of Hematology·Angelo MaiolinoUNKNOWN Brazilian Multiple Myeloma Study Group (BMMSG/GEMOH)
Jul 14, 2012·Blood·Laura RosiñolUNKNOWN Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Oct 24, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz LudwigJean-Luc Harousseau
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jesús F San MiguelPaul G Richardson
Jun 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andy C RawstronRoger G Owen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.